Pharma & R&D
Camurus Hormone Disorder Drug Faces Another FDA Delay
What's happening
Camurus said its hormone-disorder treatment is now unlikely to receive FDA approval until 2027 after encountering another regulatory setback. The company must address additional FDA concerns before the review process can move forward.
What's changing / Business impact
The delay pushes back potential revenue and creates uncertainty around the drug's commercial timeline. Regulatory delays can be especially difficult for smaller healthcare companies that depend on a limited number of products.
Why this matters
An FDA delay does not necessarily mean a drug is ineffective or unsafe. However, additional review requirements can add months or years to development timelines and significantly increase costs. Patients waiting for new treatment options may also face longer delays before gaining access.